nocodazole has been researched along with Parkinson Disease, Secondary in 1 studies
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fanara, P | 1 |
| Wong, PY | 1 |
| Husted, KH | 1 |
| Liu, S | 1 |
| Liu, VM | 1 |
| Kohlstaedt, LA | 1 |
| Riiff, T | 1 |
| Protasio, JC | 1 |
| Boban, D | 1 |
| Killion, S | 1 |
| Killian, M | 1 |
| Epling, L | 1 |
| Sinclair, E | 1 |
| Peterson, J | 1 |
| Price, RW | 1 |
| Cabin, DE | 1 |
| Nussbaum, RL | 1 |
| Brühmann, J | 1 |
| Brandt, R | 1 |
| Christine, CW | 1 |
| Aminoff, MJ | 1 |
| Hellerstein, MK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Proof-of-Concept Clinical Research Study of Efavirenz in Patients With Alzheimer's Disease[NCT03706885] | Phase 1 | 5 participants (Actual) | Interventional | 2018-05-05 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for nocodazole and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Cerebrospinal fluid-based kinetic biomarkers of axonal transport in monitoring neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Amyloid beta-Protein Precursor; Anima | 2012 |